micro-community-banner
Profile Image
  • Saved

Is There Less Aggressive Lipid Management in PAD Patients? - American College of Cardiology

Is There Less Aggressive Lipid Management in PAD Patients? - American College of Cardiology

Source : https://www.acc.org/latest-in-cardiology/articles/2021/06/14/20/40/is-there-less-aggressive-lipid-management-in-pad-patients

For patients with peripheral artery disease (PAD), intensity of lipid-lowering therapy may be a "poor surrogate" for achieved LDL-cholesterol (LDL-C), as achieved LDL-C levels remain elevated for the majority of...

Profile Image
  • Saved

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Source : https://www.cureus.com/articles/61261-atrial-fibrillation-as-a-possible-adverse-reaction-to-evolocumab

Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease....

Profile Image
  • Saved

Profile Image
  • Saved

Management of Dyslipidemia in Patients with Diabetes - touchENDOCRINOLOGY

Source : https://doi.org/10.17925/USE.2011.07.01.40

In association with the global spread of abdominal adiposity, the worldwide prevalence of type 2 diabetes continues to increase.1 This is one of the pivotal factors underscoring the projection that...

Profile Image
  • Saved

Profile Image